ClinicaliQ Trial Snapshot
- Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC — Active Not Recruiting • Phase III • Oncology • NCT04821622.
- Adding talazoparib to enzalutamide improves outcomes in men with metastatic prostate cancer and DNA repair gene mutations.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide compared with placebo in combination with enzalutamide in participants with DDR-deficient mCSPC. Conditions: Prostate Cancer Interventions: talazoparib plus enzalutamide, Placebo plus enzalutamide Lead Sponsor: Pfizer Planned Enrollment: 599 participants